Ciprofloxacin treatment failure in a case of typhoid fever caused by Salmonella enterica serotype Paratyphi A with reduced susceptibility to ciprofloxacin

Journal of Medical Microbiology

Volumn 56, Issue PART 2, 2007, Pages 277-279

  Dimitrov, Tzonyo ^a   Udo, Edet E ^b   Albaksami, Osama ^a   Kilani, Abdul A ^a   Shehab, El Din M R ^a  

^a Infectious Diseases Hospital Kuwait   (Kuwait)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; FEMALE; HUMAN; INDIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SALMONELLA PARATYPHI; TRAVEL; TREATMENT FAILURE; TYPHOID FEVER;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTRIAXONE; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; PARATYPHOID FEVER; SALMONELLA PARATYPHI A; TREATMENT FAILURE;

EID: 33847181741     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46773-0     Document Type: Article

References (14)

1. Asna, S. M., Hag, J. A. & Rahma, M. M. (2003). Nalidixic acid resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. Jpn J Infect Dis 56, 32-33.
2. Chandel, D. S., Chaudhry, R., Dhawan, B., Pandey, A. & Dey, A. B. (2000). Drug-resistant Salmonella enterica serotype Paratyphi A in India. Emerg Infect Dis 6, 420-421.
3. Dimitrov, Ts., Panigrahi, D., Emara, M., Al-Nakkas, A., Awni, F. & Passadilla, R. (2005). Incidence of bloodstream infections in a speciality hospital in Kuwait: 8-years experience. Med Princ Pract 14, 417-421.
4. Giraud, E., Brisabois, A., Martel, J.-L. & Chaslus-Dancla, E. (1999). Comparative studies of mutations in animal isolates and experimental in vitro and in vivo-selected mutants of Salmonella spp. suggest a counter selection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother 43, 2131-2137.
5. Hakanen, A., Kotilainen, P., Jalava, J. & Siitonen, A. (1999). Detection of decreased fluoroquinolone susceptibility and validation of nalidixic acid screening test. J Clin Microbiol 37, 3572-3577.
6. Hakanen, A., Kotilainen, P., Huovinen, P., Helenius, H. & Siitonen, A. (2001). Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis 7, 996-1003.
7. National Committee for Clinical Laboratory Standards (2005). Methods for Disk Susceptibility Tests for Bacteria that Grow Aerobically, NCCLS Document M2-A8, 7th edn. Wayne, PA: National Committee for Clinical Laboratory Standards.
8. Nkemngu, N. J., Asonganyi, E. D. & Njunda, A. L. (2005). Treatment failure in a typhoid patient infected with nalidixic acid resistant S. enterica serovar Typhi with reduced susceptibility to ciprofloxacin: a case report from Cameroon. BMC Infect Dis 5, 49.
9. Parry, C. M., Hien, T. T., Dougan, G., White, N. J. & Farrar, J. J. (2002). Typhoid fever. N Engl J Med 347, 17-82.
10. Piddock, L. J. (2002). Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. FEMS Microbiol Rev 26, 3-16.
11. Poutanen, S. & Low, D. E. (2003). Is it time to change fluoroquinolones MIC breakpoints for Salmonella spp.? Clin Microbiol Newsl 25, 97-102.
12. Threlfall, E. J. & Ward, L. R. (2001). Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. Emerg Infect Dis 7, 448-450.
13. Umasankar, S., Wall, R. A. & Berger, J. (1992). A case of ciprofloxacin-resistant typhoid fever. CDR Rev 2, R139-140.
14. Wain, J., Hoa, N. T. T., Chinh, N. T., Vinh, H., Everett, M. J. & Diep, T. S. (1997). Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 25, 1404-1410.